Aptar Pharma has expanded production capacity in Eigeltingen, Germany, to support large-scale production services for preservative-free ophthalmic and nasal drugs. The expansion includes the scale-up of the Ophthalmic Squeeze Dispenser (OSD) technology as well as adds new capacity for the Advanced Preservative-Free System (APF) technology, Aptar Pharma reports.
Aptar Pharma’s OSD technology is designed for multiple administrations of unpreserved eye-care medications. Aptar Pharma has invested in additional state-of-the-art equipment and more than quintupled its production capacities since September 2011, it reports in a press release. OSD is manufactured in large quantities in ISO 7 cleanrooms with state-of-the-art assembly and testing technology.
“At Aptar Pharma, we are extremely pleased to announce the scale-up of the OSD technology. OSD is the result of innovation and continuous improvement to our preservative-free technology platform range and provides several benefits to patients and consumers. We still continue to improve our high quality devices and anticipate our customers’ future needs and expectations”, stated Matthias Birkhoff, Vice President Business Development for Aptar Pharma CHC Division, in the release.
Aptar Pharma’s APF pump technology can also be used to dispense unpreserved formulations. Aptar Pharma doubled its production capacities for APF in 2012.
“APF has been a great product for Aptar Pharma. In particular, our customers in the emerging markets like Latin America or Russia market their nasal spray products equipped with APF with increasing success,” stated Gunter Nadler, Director Business Development for Aptar Pharma CHC Division, in the release.
For more information, visit www.aptar.com .